Strategic partnerships Hepregen already collaborates with over 20 pharmaceutical companies using the HepatoPac platform, indicating a receptive market and established channel for expansion and co-development opportunities.

Targeted pipeline fit The HepatoPac system offers predictive toxicity screening, DMPK and safety insights, and potential efficacy assessments for liver-focused drugs, signaling strong upsell potential to firms seeking integrated preclinical solutions.

Clinical impact focus A mission centered on transforming safety assessment and patient outcomes can be leveraged to position HepatoPac as a differentiator for sponsors prioritizing translational liver models and more reliable preclinical data.

SMB to mid-market reach Current team size and revenue range suggest an opportunity to upsell to growing biotech and mid-sized pharma companies seeking scalable, cost-efficient liver model capabilities within existing procurement frameworks.

Expansion enablers With a proven microfabrication based liver model and compatibility with high content screening, there is a clear path to expand into additional disease models, stem cell integrations, and diseased liver workflows to broaden the customer base.